Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
Lee, Rebecca J
Lorigan, Paul C
AffiliationPeter MacCallum Cancer Centre, Melbourne, Australia
MetadataShow full item record
AbstractBACKGROUND: The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify patients based on risk of relapse given the cost and toxicities associated with treatment. Here we assessed circulating tumor DNA (ctDNA) to predict and monitor relapse in resected stage III melanoma. PATIENTS AND METHODS: Somatic mutations were identified in 99/133 (74%) patients through tumor tissue sequencing. Personalized droplet digital PCR (ddPCR) assays were used to detect known mutations in 315 prospectively collected plasma samples from mutation-positive patients. External validation was performed in a prospective independent cohort (n?=?29). RESULTS: ctDNA was detected in 37 of 99 (37%) individuals. In 81 patients who did not receive adjuvant therapy, 90% of patients with ctDNA detected at baseline and 100% of patients with ctDNA detected at the postoperative timepoint relapsed at a median follow up of 20?months. ctDNA detection predicted patients at high risk of relapse at baseline [relapse-free survival (RFS) hazard ratio (HR) 2.9; 95% confidence interval (CI) 1.5-5.6; P?=?0.002] and postoperatively (HR 10; 95% CI 4.3-24; P?<?0.001). ctDNA detection at baseline [HR 2.9; 95% CI 1.3-5.7; P?=?0.003 and postoperatively (HR 11; 95% CI 4.3-27; P?<?0.001] was also associated with inferior distant metastasis-free survival (DMFS). These findings were validated in the independent cohort. ctDNA detection remained an independent predictor of RFS and DMFS in multivariate analyses after adjustment for disease stage and BRAF mutation status. CONCLUSION: Baseline and postoperative ctDNA detection in two independent prospective cohorts identified stage III melanoma patients at highest risk of relapse and has potential to inform adjuvant therapy decisions.
CitationTan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol. 2019.
JournalAnnals of Oncology
- Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.
- Authors: Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R
- Issue date: 2018 Feb 1
- Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
- Authors: Lee JH, Saw RP, Thompson JF, Lo S, Spillane AJ, Shannon KF, Stretch JR, Howle J, Menzies AM, Carlino MS, Kefford RF, Long GV, Scolyer RA, Rizos H
- Issue date: 2019 May 1
- Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.
- Authors: Marczynski GT, Laus AC, Dos Reis MB, Reis RM, Vazquez VL
- Issue date: 2020 Oct 29
- Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
- Authors: Seremet T, Planken S, Schreuer M, Jansen Y, Delaunoy M, El Housni H, Lienard D, Del Marmol V, Heimann P, Neyns B
- Issue date: 2018 Feb
- Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
- Authors: Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, Roselló S, Martinez-Ciarpaglini C, Carbonell-Asins JA, Carrasco F, Ferrer-Martínez A, Bruixola G, Fleitas T, Martín J, Tébar-Martínez R, Moro D, Castillo J, Espí A, Roda D, Cervantes A
- Issue date: 2019 Nov 1